| 查看: 221 | 回复: 1 | |||
| 当前主题已经存档。 | |||
zhantian3529铁杆木虫 (正式写手)
|
[交流]
【转帖】Drug R&D Heats Up In Beijing
|
||
|
Pharmaceutical Product Development, a U.S.-based contract drug R&D firm, has agreed to acquire BioDuro, a drug discovery services supplier that mostly operates out of labs in Beijing. Separately, Merck Serono says it will spend $225 million to build a corporate research lab, also in Beijing. Together, the deals demonstrate the drug industry’s acceptance of Beijing as a worthy R&D hub. Employing about 660 people in chemistry-oriented research facilities in the Chinese capital, BioDuro was one of the first companies in either China or India to offer integrated drug discovery services from target validation all the way to the supply of clinical candidates. The four-year-old company was formed in San Diego by two California entrepreneurs, Masood Tayebi and John Oyler. In an interview last year, Oyler said he had no intention to quickly sell BioDuro at a profit, as he had done with other companies (C&EN, Feb. 4, 2008, page 11). “I’d like to be involved in the development of a new technology that could cure a major disease,” he said. “That would be spectacular.” Oyler did not respond to C&EN’s request for comments about the change of heart. BioDuro’s “management team will remain,” a PPD spokeswoman tells C&EN. PPD is buying BioDuro, she says, to “expand our drug discovery segment and better position PPD in China.” Employing 10,500 people in 38 countries, PPD is best known for its clinical and postapproval research services. Meanwhile, Merck Serono says its new Beijing lab will employ as many as 200 scientists within four years. The facility, which Merck says will be one of its key R&D hubs worldwide, will mostly manage clinical trials. Up to now, Shanghai has been more popular than Beijing for foreign companies establishing R&D operations in China. The two cities are quite different, says Han Yongxin, the Beijing-based head of China operations at the drug discovery services firm Chemizon. “Shanghai is a very well developed services- and business-oriented city. You can also do business in Beijing,” Han says, but the city’s environment is best for research. He adds that scientists in Beijing tend to stay in their jobs longer “because they’re really interested in conducting research.”—Jean-François Tremblay Chemical & Engineering News ISSN 0009-2347 Copyright © 2009 American Chemical Society 本帖关键词：drug worthy acceptance mostly supplier http://pubs.acs.org/cen/news/87/i48/8748notw6.html |
回复此楼» 猜你喜欢
SUES&NERCN课题组接受硕士生调剂 (学硕1名+专硕1名)
已经有0人回复
-
可能上不了岸？有条件的可以考虑其他出路
已经有0人回复
-
药物学论文润色/翻译怎么收费?
已经有171人回复
-
SUES&NERCN课题组接受硕士生调剂 (学硕1名+专硕1名)
已经有0人回复
-
分子对接相关经验分享
已经有0人回复
-
分子对接相关经验分享
已经有0人回复
-
求大佬收留
已经有0人回复
-
2026生物医药产业发展大会
已经有0人回复
-
国青中了
已经有23人回复
-
:D多个国家或地区的农药法规&登记情况查询网站
已经有0人回复
zhantian3529
铁杆木虫 (正式写手)
- 应助: 0 (幼儿园)
- 金币: 7675.6
- 帖子: 958
- 在线: 126.9小时
- 虫号: 703421
- 注册: 2009-02-18
- 性别: GG
- 专业: 药物化学
|
In an interview last year, Oyler said he had no intention to quickly sell BioDuro at a profit, as he had done with other companies (C&EN, Feb. 4, 2008, page 11). “I’d like to be involved in the development of a new technology that could cure a major disease,” he said. “That would be spectacular.” Oyler did not respond to C&EN’s request for comments about the change of heart. John Oyler,这个专门办公司然后再卖了的投资者 |
2楼2009-12-03 16:47:54
